Trials / Recruiting
RecruitingNCT05851456
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Shanghai Yunying Medical Technology · Industry
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory bone and soft tissue tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant oncolytic herpes simplex virus type Ⅰ (R130) | R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11 |
Timeline
- Start date
- 2023-04-10
- Primary completion
- 2025-04-01
- Completion
- 2026-04-01
- First posted
- 2023-05-09
- Last updated
- 2023-05-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05851456. Inclusion in this directory is not an endorsement.